Growth Metrics

BioNexus Gene Lab (BGLC) Long-Term Deferred Tax (2024 - 2026)

BioNexus Gene Lab recorded quarterly Long-Term Deferred Tax of $12.2 million in Q1 2026, up 4.78% quarter-over-quarter from $11.6 million in Q4 2025.

BioNexus Gene Lab's Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $12.2 million for Q1 2026.

  • In Q1 2026, Long-Term Deferred Tax changed N/A year-over-year to $12.2 million; the TTM figure through Mar 2026 stood at $12.2 million (changed N/A YoY), while the FY2025 annual figure was $11.6 million, changed N/A from the prior year.
  • Long-Term Deferred Tax came in at $12.2 million for Q1 2026 at BioNexus Gene Lab, up from $11.6 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $12.2 million in Q1 2026 to a low of $11.6 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Linde 230.79 Bn 226.84 Bn 4.26 Bn
2 Chemical & Mining Co Of Chile 127.66 Bn 124.93 Bn 778.60 Mn
3 Sherwin Williams 72.51 Bn 72.30 Bn 2.78 Bn
4 Ecolab 70.96 Bn 70.34 Bn 1.85 Bn
5 Air Products & Chemicals 62.15 Bn 63.70 Bn 987.40 Mn
6 Ppg Industries 25.04 Bn 23.57 Bn 1.66 Bn
7 LyondellBasell Industries 21.62 Bn 21.73 Bn 701.00 Mn
8 Albemarle 20.26 Bn 19.42 Bn 500.97 Mn
9 DuPont de Nemours 19.45 Bn 19.56 Bn 602.00 Mn
10 BioNexus Gene Lab 5.34 Mn 1.38 Mn -790.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 12.16 Mn
Dec 31, 2025 11.61 Mn
Dec 31, 2024 9.40 Mn